[{"id":"fbc9f7d7-d0d2-47e2-adf9-dee22a15f587","acronym":"","url":"https://clinicaltrials.gov/study/NCT03721068","created_at":"2021-01-18T18:14:20.673Z","updated_at":"2024-07-02T16:35:08.050Z","phase":"Phase 1","brief_title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","source_id_and_acronym":"NCT03721068","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" IL15","pipe":"","alterations":" ","tags":["IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • iC9.GD2.CAR.IL-15 T-cells"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 06/19/2024","primary_completion_date":" 06/19/2024","study_txt":" Completion: 06/19/2039","study_completion_date":" 06/19/2039","last_update_posted":"2024-04-23"}]